You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,968,450


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,968,450 protect, and when does it expire?

Patent 10,968,450 protects VYONDYS 53 and is included in one NDA.

This patent has thirty patent family members in thirteen countries.

Summary for Patent: 10,968,450
Title:Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
Inventor(s): Wilton; Stephen Donald (Applecross, AU), Fletcher; Sue (Bayswater, AU), McClorey; Graham (Bayswater, AU)
Assignee: The University of Western Australia (Crawley, AU)
Application Number:16/527,886
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,968,450: A Detailed Analysis

Introduction

Patents are a cornerstone of innovation, providing inventors with exclusive rights to their creations and incentivizing further development. The United States Patent and Trademark Office (USPTO) plays a crucial role in this process, and recent updates, such as the 2024 USPTO guidance on AI patents, have significant implications for patent eligibility. This article will delve into the specifics of United States Patent 10,968,450, analyzing its scope, claims, and the broader patent landscape.

What is a Patent?

Before diving into the specifics of Patent 10,968,450, it is essential to understand what a patent is. A patent grants its owner the exclusive right to make, use, import, sell, or offer for sale the invention covered by the patent. This right is granted for a limited time in exchange for the public disclosure of the invention[2].

The Structure of a Patent

A patent typically includes several key components:

  • Cover Page: Provides basic information such as the name(s) of the inventor(s), the title of the patent, and the date it was issued.
  • Abstract: A brief summary of the invention.
  • Drawings: Illustrations of the background technology, various aspects of the invention, or different implementations of the invention[2].

Patent 10,968,450: Overview

To analyze Patent 10,968,450, we need to look at its specific components:

Title and Abstract

The title and abstract provide the first glimpse into what the patent covers. For example, if the patent is related to AI or software, the abstract will outline the core innovation and its practical applications.

Claims

The claims section is critical as it defines the legal boundaries of the invention. Claims must be sufficiently clear and must adequately describe the invention to meet the written description requirement[2].

Independent and Dependent Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit the independent claims, often adding additional features or details[2].

Drawings and Specifications

The drawings and specifications provide detailed descriptions and visual representations of the invention. These are crucial for understanding how the invention works and its various implementations.

Patent Eligibility and the 2024 USPTO Guidance

The 2024 USPTO guidance update on AI patents is particularly relevant when analyzing the eligibility of patents like 10,968,450. Here are some key points:

Evaluating Practical Applications

The guidance emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Incorporation of Recent Case Law

The guidance incorporates recent case law to provide clearer examples of patent-eligible and ineligible claims. For instance, claims that specify the use of abstract ideas in real-world applications, such as improving speech recognition systems, are more likely to be considered patent-eligible[1].

Real-World Applications and Practical Utility

To be patent-eligible, claims must demonstrate real-world applications and practical utility. For example, if a claim merely uses a mathematical model to manipulate data without applying it in a specific manner, it is unlikely to be considered patent-eligible. However, if the claim specifies the use of the data in a practical application, such as enhancing the accuracy of voice commands in hands-free environments, it is more likely to meet the criteria for patent eligibility[1].

The Broader Patent Landscape

Economic Impact of Patents

Patents have a significant economic impact. In 2019, the USPTO issued 354,507 new patents, the most in its history. Patent-intensive industries added 3.9 million jobs to the U.S. economy and contributed $881 billion to the U.S. GDP, comprising 5.1% of the U.S. GDP[2].

Technological and Healthcare Significance

Patents are crucial in technology and healthcare. For instance, a single smartphone may be protected by as many as 250,000 patents. New pharmaceuticals are often protected by numerous patents, with one study finding that pharmaceutical manufacturers obtained an average of seventy-one patents on each of the top twelve drugs by gross U.S. revenue[2].

Case Law and Administrative Proceedings

Patent eligibility and validity can be challenged through various legal and administrative proceedings. For example, the case of In re Cellect highlights the complexities of patent term adjustments and the importance of performing an Office Delayed Prosecution (ODP) analysis to determine the validity of patent claims[4].

Key Takeaways

  • Patent Eligibility: The 2024 USPTO guidance emphasizes the importance of integrating judicial exceptions into practical applications to ensure patent eligibility.
  • AI-Assisted Inventions: AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution.
  • Real-World Applications: Demonstrating practical utility and real-world applications is crucial for patent eligibility.
  • Economic Impact: Patents significantly contribute to the economy and job creation.
  • Technological and Healthcare Significance: Patents are vital in protecting innovations in technology and healthcare.

FAQs

What is the main focus of the 2024 USPTO guidance update on AI patents?

The main focus is on refining and clarifying the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications.

How do AI-assisted inventions impact patent eligibility?

AI-assisted inventions are evaluated on equal footing with other technologies, with the focus remaining on the claimed invention itself rather than the method of invention development.

What makes a claim patent-eligible according to the 2024 USPTO guidance?

A claim is patent-eligible if it integrates a judicial exception into a practical application, imposing meaningful limits on the exception and providing concrete technological improvements.

How do patents contribute to the economy?

Patents contribute significantly to the economy by adding jobs and value to the GDP. In 2019, patent-intensive industries added 3.9 million jobs and $881 billion to the U.S. GDP.

What is the role of patents in technology and healthcare?

Patents protect innovations in technology and healthcare, such as smartphones and new pharmaceuticals, encouraging research and development by providing exclusive rights to inventors.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Patent Law: A Handbook for Congress - Congressional Research Service
  3. Patent Claims Research Dataset - USPTO
  4. In re Cellect - United States Court of Appeals for the Federal Circuit
  5. U.S. Patent and Trademark Office (USPTO) - USAGov

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,968,450

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sarepta Theraps Inc VYONDYS 53 golodirsen SOLUTION;INTRAVENOUS 211970-001 Dec 12, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.